A cou­ple months af­ter land­ing $100 mil­lion in fund­ing, Cel­lares grabs part­ner for its Cell Shut­tle

The team at Cel­lares hopes that its Cell Shut­tle is the fu­ture of end-to-end cell ther­a­py man­u­fac­tur­ing. On Wednes­day, the com­pa­ny an­nounced that one more com­pa­ny has signed up to work along­side it.

Po­sei­da has signed on to pro­vide ther­a­pies for the Cell Shut­tle, a portable fac­to­ry Cel­lares hopes will dis­rupt the ex­pen­sive and lo­gis­ti­cal­ly com­pli­cat­ed cell ther­a­py man­u­fac­tur­ing process. The com­pa­ny is the third to ink a deal with Cel­lares, which is based out of South San Fran­cis­co, CA. Cel­lares has al­ready has been col­lab­o­rat­ing with PACT Phar­ma and the Fred Hutchin­son Can­cer Re­search Cen­ter.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER